Celyad Oncology
ENXTBR:CYAD
0,31
€-0,01 (-3,13%)
0,31
€-0,01 (-3,13%)
End-of-day quote: 04/01/2026

Quick Analysis
The traffic-light system summarizes key characteristics and shows the investment’s quality at a glance.

€-1,70
Earnings Per Share
€0,00
Revenue Per Share
93,55%
Gross Margin %
€0,01 B
Market Cap
€0,00 B
Long-Term Debt
Earnings Per Share
€-1,70
Revenue Per Share
€0,00
Gross Margin %
93,55%
Market Cap
€0,01 B
Long-Term Debt
€0,00 B

Financials

Year Year 2024 2021 2020 2019 2018 2017 2016 2015 2014 2013
EPS Earnings Per Share €-1,70 €-1,70 €-1,23 €-2,29 €-3,36 €-3,13 €-2,53 €-3,43 €-2,44 €-3,01
Earnings Earnings €-70,43M €-38,40M €-17,48M €-31,92M €-40,12M €-30,89M €-24,09M €-31,93M €-22,72M €-19,05M
RPS Revenue Per Share €0,00 €0,00 €0,00 €0,00 €0,26 €0,36 €0,89 €0,00 €0,02 €0,00
Revenue Revenue €0,00M €0,00M €0,01M €0,01M €3,12M €3,54M €8,52M €0,00M €0,15M €0,00M
OCF Operating Cash Flow €-26,64M €-26,64M €-27,67M €-28,20M €-27,29M €-49,55M €-24,69M €-27,30M €-17,41M €-10,64M
FCF Free Cash Flow €0,00M €-26,97M €-27,82M €-28,62M €-28,13M €-50,40M €-26,47M €-28,14M €-18,05M €-10,71M
OM Operating Margin 0,00% 0,00% 0,00% 0,00% 0,00% 0,00% -255,78% 0,00% 0,00% 0,00%
GM % Gross Margin % 93,55% 0,00% 100,00% 100,00% 100,00% 85,45% 84,60% 33,33% 21,23% 0,00%
FCFS Free Cash Flow Per Share €-0,14 €-1,73 €-2,01 €-2,30 €-2,60 €-4,71 €-3,01 €-3,32 €-2,67 €-2,72
LT Debt Long-Term Debt N/A N/A N/A €0,04M €0,23M €0,33M €0,54M N/A N/A N/A
Sha. Stocks 41,43M 22,59M 14,21M 13,94M 11,94M 9,87M 9,52M 9,31M 9,31M 6,33M
×